Could autoimmunity be induced by vaccination

International Reviews of Immunology

Volumn 29, Issue 3, 2010, Pages 247-269

  Salemi, Simonetta ^a   D'Amelio, Raffaele ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Direzione Generale della Sanita Militare   (Italy)

Author keywords

Autoimmune diseases; Insulin dependent diabetes mellitus; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; Vaccinations; Vasculitides

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FREUND ADJUVANT; HEPATITIS B VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MYELIN BASIC PROTEIN; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; SMALLPOX VACCINE; STREPTOCOCCUS VACCINE; SWINE INFLUENZA VACCINE; TETANUS TOXOID; TYPHOID VACCINE; YELLOW FEVER VACCINE; VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY BLOOD LEVEL; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN DISEASE; CAUSAL ATTRIBUTION; CEREBROSPINAL FLUID LEVEL; DISEASE PREDISPOSITION; DRUG SAFETY; ENCEPHALOMYELITIS; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; MYELITIS; NEURITIS; NEUROLOGICAL COMPLICATION; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VACCINATION; VASCULITIS; ANIMAL; AUTOIMMUNE DISEASES; BYSTANDER EFFECT; DRUG EFFECTS; IMMUNOLOGY; INFECTION CONTROL; RISK FACTOR;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BYSTANDER EFFECT; COMMUNICABLE DISEASE CONTROL; DISEASE SUSCEPTIBILITY; HUMANS; MOLECULAR MIMICRY; RISK FACTORS; VACCINATION; VACCINES;

EID: 77953195598     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830181003746304     Document Type: Review

References (174)

1. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994; 271: 1602-1605.
2. Benoist C, Mathis D. Autoimmunity provoked by infection: How good is the case for T cell epitope mimicry? Nat Immunol 2001; 2: 797-801.
3. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune diseases: What is the evidence? Lancet 2003; 362: 1659-1666.
4. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation or viral persistence: Infections and autoimmune disease. Clin Microbiol Rev 2006; 19: 80-94.
5. Zabriskie JB, Freimer EH. An immunological relationship between the group. A streptococcus and mammalian muscle. J Exp Med 1966; 124: 661-678.
6. Fujinami RS, Oldstone MBA, Wroblewska Z, et al. Molecular mimicry in virus infection: Cross reaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A 1983; 80: 2346-2350.
7. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity. Science 1985; 230: 1043-1045.
8. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19: 395-404.
9. Miller SD, Olson JK, Croxford JL. Multiple pathways to induction of virus-induced autoimmune demyelination: Lessons from Theiler's virus infection. J Autoimmun 2001; 16: 219-227.
10. Horwitz MS, Bradley LM, Harbertson J, et al. Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4: 781-785.
11. Raveche ES, Schutzer SE, Fernandes H, et al. Evidence of Borrelia autoimmunity-induced component of Lyme carditis and arthritis. J Clin Microbiol 2005; 43: 850-856.
12. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991; 338: 1174-1175.
13. Touze E, Gout O, Verdier-Taillefer MH, et al. The first episode of central nervous system demyelinization and hepatitis B vaccination. Rev Neurol 2000; 156: 242-246.
14. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7: 939-950.
15. Nachamkin I, Shadomy SV, Moran AP, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: Insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis 2008; 198: 226-233.
16. Chen RT, Pless R, DeStefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001; 16: 309-318.
17. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005; 23: 3876-3886.
18. Anon. Causality assessment for adverse events following immunization. Wkly Epidemiol Rec 2001; 76: 85-92.
19. Agmon-Levin N, Zafrir Y, Paz Z, et al. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 2009; 18: 1192-1197.
20. Aho K, Kottinen A, Rajasalmi M, Werger O. Transient appearance of rheumatoid factor in connection with prophylactic vaccinations. Acta Path Microbiol Scand 1962; 56: 478-479.
21. Palit J, Chattopadhyay C, Malaviya AN, et al. Some immunological parameters in rheumatoid arthritis from India. Biomedicine 1977; 27: 70-73.
22. D'Amelio R, Tagliabue A, Nencioni L, et al. Comparative analysis ofimmunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect Immun 1988; 56: 2731-2735.
23. Krutitskaya L, Tokarevich N, Zhebrun A, et al. Autoimmune component in individuals during immune response to inactivated combined vaccine against Q fever. Acta Virol. 1996; 40: 173-177.
24. Toplak N, Avčin T. Vaccination of healthy subjects and autoantibodies: From mice through dogs to humans. Lupus 2009; 18: 1186-1191.
25. Wucherpfennig KW, Stominger JL. Molecular mimicry in T cell-mediated autoim-munity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
26. Offitt PA, Hackett CJ. Addressing parents' concerns: Do vaccines cause allergic or autoimmune diseases? Pediatrics 2003; 111: 653-658.
27. Nadler JP. Multiple sclerosis and hepatitis B vaccination. Clin Infect Dis 1993; 17: 928-929.
28. Fourrier A, Touze E, Alperovitch A, Begaud B. Association between hepatitis B vaccine and multiple sclerosis: A case-control study. Pharmacoepidemiol Drug Saf 1999; 8(suppl):S140-S141.
29. Sturkenboom MCJM, Abenhaim L, Wolfson C, et al. Vaccinations, demyelination, and multiple sclerosis study (VDAMS): A population based study in the UK. Phar-macoepidemiol Drug Saf 1999; 8(suppl):S170-S171.
30. Gout O, Lyon Caen O. Sclerotic plaques and vaccination against hepatitis B. Rev Neurol 1998; 154: 205-207.
31. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 334: 327-332.
32. Stratton K, Almario DA, McCormick MC. Editors, Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders (Free Executive Summary). 2002. Retrieved from http://www.nap.edu/catalog/10393.html
33. Girard M. Autoimmune hazards of hepatitis B vaccine. Autoimmun Rev 2005; 4: 96-100.
34. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study. Neurology 2004; 63: 838-842.
35. Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009; 72: 873-880.
36. Ness JM, Bale JF. Hepatitis B vaccines and paediatric multiple sclerosis. Does timing or type matter? Neurology 2009; 72: 870-871.
37. Ju YY, Womersley H, Pritchard J, et al. Haemophilus influenzae as a possible cause of Guillain-Barré syndrome. J Neuroimmunol 2004; 149: 160-166.
38. Kinnunen E, Junttila O, Haukka J, Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré syndrome. Am J Epidemiol 1998; 147: 69-73.
39. Rantala H, Cherry JD, Shields WD, Uhari M. Epidemiology of Guillain-Barré in children: Relationship of oral poliovaccine administration to occurrence. J Pediatr 1994; 124: 220-223.
40. Shoenfeld Y, Aaron-Maor A. Vaccination and autoimmunity - Vaccinosis: A dangerous liaison. J Autoimmun 2000; 14: 1-10.
41. Langmuir AD. Guillain-Barré syndrome: The swine influenza virus vaccine incident in the United States of America, 1976-77: Preliminary communication. J R Soc Med 1979; 72: 660-669.
42. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979; 110: 105-123.
43. Marks JS, Halpin TJ. Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA 1980; 243: 2490-2494.
44. Belshe RB. Implications of the emergence of a novel H1 influenza virus. N Engl J Med 2009; 360: 2667-2668.
45. Eisen DP, McBryde ES. Avoiding Guillain-Barré syndrome following swine origin pandemic H1N1 2009 influenza vaccination. J Infect Dis 2009; 200: 1627-1628.
46. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339: 1797-1802.
47. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination in adults: A population-based study. Arch Intern Med 2006; 166: 2217-2221.
48. Stratton K, Alamario DA, Wizemann T, McCormick MC. Editors, Immunization Safety Review: Influenza Vaccine and Neurological Complications (Free Executive Summary). 2004. Retrieved from http://www.nap.edu/catalog/10822.html
49. Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703-706.
50. Alaedini A, Latov N. Antibodies against OspA epitopes of Borrelia burgdorferi cross-react with neural tissue. J Neuroimmunol 2005; 159: 192-195. Epub Nov. 26, 2004.
51. Ball R, Shadomy SV, Meyer A, et al. HLA type and immune response to Bor-relia burgdorferi outer surface protein A in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum 2009; 60: 1179-1186. doi: 10.1002/art.24418
52. Willett TA, Meyer AL, Brown EL, Huber BT. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci USA 2004; 101: 1303-1308. Epub Jan. 23, 2004.
53. Fenderson PG, Fischetti VA, Cunningham MW. Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. J Immunol 1989; 142: 2475-2481.
54. Guilherme L, Faé KC, Higa F, et al. Towards a vaccine against rheumatic fever. Clin Dev Immunol 2006; 13: 125-132.
55. Jennings HJ. Capsular polysaccharides as vaccine candidates. Curr Top Microbiol Immunol 1990; 150: 97-127.
56. Edelman GM. Cell adhesion molecules. Science 1983; 219: 450-457.
57. Finne J. Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. J Biol Chem 1982; 257: 11966-11970.
58. Rutishauser U. Polysialic acid and the regulation of cell interactions. Curr Opin Cell Biol 1996; 8: 679-684.
59. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2: 355-357.
60. Frasch CE, Robbins JD. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med 1978; 147: 629-644.
61. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197: 789-799.
62. Stein DM, Robbins J, Miller MA, et al. Are antibodies to the capsular polysac-charide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? Vaccine 2006; 24: 221-228.
63. Torisu M, Miyahara T, Shinohara N, et al. A new side effect of BCG immuno-therapy-BCG-induced arthritis in man. Cancer Immunol Immunother 1978; 5: 77.
64. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG im-munotherapy for urinary bladder carcinoma: A systematic review. Rheumatol Int 2006; 26: 481-488. doi: 10.1007/s00296-005-0059-2
65. El Mahou S, Popa L, Constantin A, et al. Remitting seronegative symmetrical syn-ovitis pitting oedema after BCG instillation. Clin Rheumatol 2006; 25: 566-567. Epub Mar. 25, 2006.
66. Moutzouris DA, Manetas S, Mountantonakis SE. Acute polyarthritis after bacilli Calmette-Guerin intravesical therapy for bladder carcinoma. J Clin Rheumatol 2006; 12: 214-215.
67. Manzini CU, Bernini L, Elkhaldi N, et al. Dactilitis and oligoarthritis after BCG immunotherapy in a patient affected by bladder cancer. Reumatismo 2006; 58: 230-232.
68. Tektonidou MG. Reiter's syndrome during intravesical BCG therapy for bladder carcinoma. Clin Rheumatol 2007; 26: 1368-1369. Epub Aug. 16, 2006.
69. Rincón Mayans A, Zudaire Bergera JJ, Brugarolas Rosselló J, et al. Polyarthritis secondary to intravesical BCG instillation, a case report. Actas Urol Esp 2007; 31: 400-403.
70. Spratt A, Key T, Vivian AJ. Chronic anterior uveitis following bacille Calmette-Guérin vaccination: Molecular mimicry in action? J Pediatr Ophthalmol Strabismus 2008; 45: 252-253.
71. Garip A, Diedrichs-Möhring M, Thurau SR, et al. Uveitis in a patient treated with Bacille-Calmette-Guérin: Possible antigenic mimicry of mycobacterial and retinal antigens. Ophthalmology 2009; 116: 2457-2462.e1-2. Epub Oct. 7, 2009.
72. Glynn P, Weedon D, Edwards J, et al. Humoral immunity in chronic relapsing experimental autoimmune encephalomyelitis. The major oligoclonal IgG bands are antibodies to mycobacteria. J Neurol Sci 1982; 57: 369-384.
73. van Eden W, Holoshitz J, Nevo Z, et al. Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci 1985; 82: 5117-5120.
74. Thorns CJ, Morris JA. Common epitopes between mycobacteria and certain host tissue antigens. Clin Exp Immunol 1985; 61: 323-328.
75. Shoenfeld Y, Vilner Y, Coatest ARM, et al. Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobac-terium tuberculosis. Clin Exp Immunol 1986; 66: 255-261.
76. Harkonen T, Lankinen H, Davydova B, et al. Enterovirus infection can induce immune responses that cross-react with beta-cell autoantigen tyrosine phosphatase IA-2/IAR. J Med Virol 2002; 66: 340-350.
77. Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes au-toantigen tyrosine phosphatase IA-2: Potential for mimicry with rotavirus and other environmental agents. Mol Med 1998; 4: 231-239.
78. Hiemstra HS, Schloot NC, van Veelen PA, et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci USA 2001; 98: 3988-3991.
79. Ou D, Mitchell LA, Metzger DL, et al. Cross-reactive rubella virus and glutamic acid decarboxylase (65 and 67) protein determinants recognised by T cells of patients with type I diabetes mellitus. Diabetologia 2000; 43: 750-762.
80. Härkönen T, Paananen A, Lankinen H, et al. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans. J Med Virol 2003; 69: 426-440.
81. Kelly KJ, Yoon JW. Rubella virus-induced diabetes in the hamster. Diabetes 1986; 35: 1278-1281.
82. Numazaki K, Goldman H, Wong I, et al. Infection of cultured human fetal pancreatic islet cells by rubella virus. Am J Clin Pathol 1989; 91: 446-451. (Pubitemid 19097073)
83. Numazaki K, Goldman H, Seemayer TA, et al. Infectionbyhuman cytomegalovirus and rubella virus of cultured human fetal islets of Langerhans. In Vivo 1990; 4: 49-54.
84. Numazaki K, Goldman H, Wong I, et al. Viral-infection of human-fetal islets of langerhans - replication of human cytomegalo-virus in cultured human-fetal pancreatic-islets. Am J Clin Pathol 1988; 90: 52-57.
85. Vuorinen T, Nikolakaros G, Simell O, et al. Mumps and Coxsackie B3 virus infection of human fetal pancreatic islet-like cell clusters. Pancreas 1992; 7: 460-464.
86. Hyöty H, Hiltunen M, Reunanen A, et al. Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Childhood Diabetes in Finland Study Group. Diabetologia 1993; 36: 1303-1308.
87. Cavallo MG, Baroni MG, Toto A, et al. Viral infection induces cytokine release by beta islet cells. Immunology 1992; 75: 664-668.
88. Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study: Vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 1991; 34: 176-181.
89. Shehadeh N, Etzioni A, Cahana A, et al. Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice. Isr J Med Sci 1997; 33: 711-715.
90. Sinaniotis CA, Daskalopoulou E, Lapatsanis P, Doxiadis S. Diabetes mellitus after mumps vaccination. Arch Dis Child 1975; 50: 749-750.
91. Lista F, Faggioni G, Peragallo MS, et al. Molecular analysis of early postvaccine mumps-like disease in Italian military recruits. JAMA 2002; 288: 1114-1115.
92. Hiltunen M, Hyöty H, Leinikki P, et al. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children. Diabet Med 1994; 11: 942-946.
93. Parent M, Fritschi L, Siemiatycki J, et al. Bacille Calmette- Guérin vaccination and incidence of IDDM in Montreal, Canada. Diabetes Care 1997; 20: 767-772.
94. Elliott JF, Marlin KL, Couch RM. Effect of Bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care 1998; 21: 1691-1693.
95. Baik SH, Park IB, Choi KM, et al. BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice. Diabetes Res Clin Pract 1999; 46: 91-97.
96. Sanjeevi CB, Das AK, Shtauvere-Brameus A. BCG vaccination and GAD65 and IA-2 autoantibodies in autoimmune diabetes in Southern India. Ann. NY Acad Sci 2002; 958: 293-296.
97. Baxter AG, Horsfall AC, Healey D, et al. Mycobacteria precipitates an SLE-like syndrome in diabetes-prone NOD mice. Immunology 1994; 83: 227-231.
98. Pozzilli P on behalf of the IMDIAB group. BCG vaccine in insulin-dependent diabetes mellitus. Lancet 1997; 349: 1520-1521.
99. Classen JB, Classen DC. Vaccines modulate IDDM. Diabetologia 1996; 39: 500-502.
100. Jefferson T, Demicheli V. No evidence that vaccines cause insulin dependent diabetes mellitus. J Epidemiol Community Health 1998; 52: 674-675.
101. Classen DC, Classen JB. Association between type 1 diabetes and Hib vaccine. BMJ 1999; 319: 1133.
102. Classen DC, Classen JB. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. Infect Dis Clin Pract 1997; 6: 449-454.
103. Karvonen M, Cepaitis Z, Tuomilehto J. Association between type 1 diabetes and Haemophilus influenzae type b vaccination: Birth cohort study. BMJ 1999; 318: 1169-1172.
104. Graves PM, Barriga KJ, Norris JM, et al. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999; 22: 1694-1697.
105. DeStefano F, Mullooly JP, Okoro CA, et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 2001; 108: E112.
106. Hviid A, Stellfield M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med 2004; 350: 1398-1404.
107. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009; 18: 1217-1225.
108. Sell E, Minassian BA. Demystifying vaccination-associated encephalopathy. Lancet Neurol 2006; 5: 465-466.
109. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Na1p3 inflam-masome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453: 1122-1126.
110. Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205: 869-882.
111. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis: An emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 1998; 352: 347-352.
112. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001; 124: 1821-1831.
113. Rousseau MC, Parent ME, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: The example of BCG vaccination. Pediatr Allergy Immunol 2008; 19: 438-448. doi: 10.1111/J.1399-3038.2007.00669
114. Matyszak MK, Perry VH. Demyelination in the central nervous system following a delayed-type hypersensitivity response to Bacillus Calmette-Guérin. Neuroscience 1995; 64: 967-977.
115. Rubinstein E. Vaccination and autoimmune diseases: The argument against. IMAJ 2004; 6: 433-435.
116. Miller E, Waight P, Farrington P, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84: 227-229.
117. Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: Review of the vaccine adverse events reporting system (1990-1994). Pediatr Infect Dis J 1997; 16: 423-424.
118. Nieminen U, Peltola H, Syrjälä MT, et al. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993; 82: 267-270.
119. Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: A retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J 1996; 15: 44-48.
120. Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46: S2-S14.
121. Rajantie J, Zeller B, Treutiger I, et al. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007; 25: 1838-1840.
122. Anon. Update: Guillain-Barré Syndrome among recipients of Menactra® meningococcal conjugate vaccine - United States, June 2005-September 2006. MMWR 2006; 55: 1120-1124.
123. Roos KL, Eckerman NL. The smallpox vaccine and post-vaccinal encephalitis. Semin Neurol 2002; 22: 95-98.
124. Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 2003; 289: 3278-282.
125. Halsell JS, Riddle JR, Atwood JE, et al. Department of Defense Smallpox Vaccination Clinical Evaluation Team. Myopericarditis following smallpox vaccination among vaccinia-näve US military personnel. JAMA 2003; 289: 3283-3289.
126. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: A multi-analysis. Lupus 2009; 18: 1198-1204.
127. Hemachudha T, Griffin DE, Giffels JJ, et al. Myelin basic protein as an encephal-itogen in encephalomyelitis and polyneuritis following rabies vaccination. N Engl J Med 1987; 316: 369-374.
128. Chaleomchan W, Hemachudha T, Sakulramrung R, Deesomchok U. Anticardi-olipin antibodies in patients with rabies vaccination induced neurological complications and other neurological diseases. J Neurol Sci 1990; 96: 143-151.
129. McMahon AW, Eidex RB, Marfin AA, et al. Yellow Fever Working Group. Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases. Vaccine 2007; 25: 1727-1734. Epub Nov. 27, 2006.
130. Monath TP. Yellow Fever Vaccine. In: Plotkin SA Orenstein WA (Eds.). Vaccines. Philadelphia: Saunders, pp. 1095-1176, 2004.
131. Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and Japanese encephalitis vaccines: Indications and complications. Infect Dis Clin North Am 2005; 19: 151-168.
132. Khromava AY, Eidex RB, Weld LH, et al. Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005; 23: 3256-3263.
133. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004:22;2103-2105.
134. Berry PA, Smith-Laing G. Hepatitis A vaccine associated with autoimmune hepatitis. World J Gastroenterol 2007; 13: 2238-2239.
135. Tavadia S, Drummond A, Evans CD, Wainwright NJ. Leucocytoclastic vasculitis and influenza vaccination. Clin Exp Derm 2003; 28: 154-156.
136. Walker SL, Swindells KJ, Chalmers RJG. Leukocytoclastic vasculitis and influenza immunization. Vaccination Clin Exp Derm 2004; 29: 91-99.
137. Mormile R, D'Alterio V, Treccagnoli G, Sorrentino P. Henoch-Schonlein purpura with antiphospholipid antibodies after influenza vaccination: How fearful is it in children? Vaccine 2004; 23: 567-568.
138. Hull JH, Mead SH, Foster OJ, Modarres-Sadeghi H. Severe vasculitic neuropathy following influenza vaccination. J Neurol Neurosurg Psych 2004; 75: 1507-1508.
139. Hyla-Klekot L, Kucharska G, Cieslak W. Necrotizing glomerulonephritis in de-cursu vasculitis after vaccination against influenza. Pol Merkur Lekarski 2005; 19: 75-77.
140. Famularo G, Nicotra GC, Minisola G, De Simone C. Leukocytoclastic vasculitis after influenza vaccination. J Clin Rheumatol 2006; 12: 48-50.
141. Pou MA, Diaz-Torne C, Vidal S, et al. Development of autoimmune diseases after vaccination. J Clin Rheumatol 2008; 14: 243-244.
142. Birck R, Kaelsch I, Schnuelle P, et al. ANCA-associated vasculitis following influenza vaccination: Causal association or mere coincidence? J Clin Rheumatol 2009; 15: 289-291.
143. Zafrir Y, Agmon-Levin N, Shoenfeld Y. Post-influenza vaccination vasculitides. A possible new entity. J Clin Rheumatol 2009; 15: 269-270.
144. Le Goff P, Fauquert P, Youinou P, Hoang S. Periarteritis nodosa following vaccination against hepatitis B. Presse Med 1988; 17:1763.
145. Vanoli M, Gambini D, Scorza R. A case of Churg-Strauss vasculitis after hepatitis B vaccination. Ann Rheum Dis 1998; 57: 256-257.
146. Allen MB, Cockwell P, Page RL. Pulmonary and cutaneous vasculitis following hepatitis B vaccination. Thorax 1993; 48: 580-581.
147. Zaas A, Scheel P, Venbrux A, Hellmann DB. Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases. J Rheumatol 2001; 28: 1116-1120.
148. De Keyser F, Naeyaert JM, Hindryckx P, et al. Immune-mediated pathology following hepatitis B vaccination. Two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol 2000; 18: 81-85.
149. Saadoun D, Cacoub P, Mahoux D, et al. Postvaccine vasculitis: A report of three cases. Rev Med Interne 2001; 22: 172-176.
150. Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin Rheumatol 2003; 22: 461-463. Epub Oct. 7, 2003.
151. Chave T, Neal C, Camp R. Henoch-Schönlein purpura following hepatitis B vaccination. J Dermatolog Treat 2003; 14: 179-181.
152. Beretta L, Caronni M, Vanoli M, Scorza R. Churg-Strauss vasculitis with brain involvement following hepatitis B vaccination. Clin Exp Rheumatol 2001; 19: 757.
153. Bourgeais AM, Dore MX, Croue A, et al. Cutaneous polyarteritis nodosa following hepatitis B vaccination. Ann Dermatol Venereol 2003; 130: 205-207.
154. Muñiz AE. Lymphocytic vasculitis associated with the anthrax vaccine: Case report and review of anthrax vaccination. J Emerg Med 2003; 25: 271-276.
155. Orbach H, Tanay A. Vaccines as a trigger for myopathies. Lupus 2009; 18: 1213-1216.
156. Ayvazian LF, Badger TL. Disseminated lupus erythematosus occurring among student nurses. N Engl J Med 1948; 88: 833-834.
157. Tudela P, Marti S, Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B. Nephron 1992; 62: 236.
158. Mamoux V, Dumont C. Lupus erythémateux disséminé et vaccination contre l'hépatite B [Lupus erythematosus disseminatus and vaccination against hepatitis B virus]. Arch Pédiatr 1994; 1: 307-308.
159. Guisérix J. Systemic Lupus Erythematosus following hepatitis B vaccination. Nephron 1996; 74: 441.
160. Finielz P, Lam-Kam-Sang LF, Guisérix J. Systemic Lupus Erythematosus and thrombocitopenic purpura in two members of the same family following hepatitis B vaccine. Nephrol Dial Transplant 1998; 13: 2420-2421.
161. Shapiro E, Kopicky J. Comment on the article Can immunization precipitate connective tissue disease? Report of 5 cases of Systemic Lupus Erythematosus and review of the literature. Semin Arthritis Rheum 2000; 30: 215-216.
162. Fineschi S. Can recombinant anti-HBV vaccine be a cause of Systemic Lupus Erythematosus? Lupus 2001; 10: 830.
163. Older A, Battafarano DF, Enzenauer RJ, Krieg A. Can immunization precipitate connective tissue disease? Report of five cases of Systemic Lupus Erythematosus and review of the literature. Semin Arthritis Rheum 1999; 29: 131-139.
164. Cooper GS, Dooley MA, Treadwell EL, et al. Risk factors for development of systemic lupus erythematosus: Allergies, infections, and family history. J Clin Epidemiol 2002; 55: 982-989.
165. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301.
166. Gross K, Combe C, Krüger K, Shattenkirchner M. Arthritis after hepatitis B vaccination. Report of three cases. Scand J Rheumatol 1995; 24: 50-52.
167. Vautier G, Carty JE. Acute seropositive rheumatoid arthritis occurring after hepatitis B vaccination. Br J Rheumatol 1994; 33: 991-998.
168. Maillefert JF, Sibilia J, Toussirot E, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 1999; 38: 978-983.
169. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J. Rheumatol 1998; 25: 1687-1693.
170. DPM Symmons, Chakravatry K. Can immunization trigger rheumatoid arthritis? Ann Rheum Dis 1993; 52: 843-844.
171. Maillefert JF, Tonolli-Serabian I, Cherasse A, et al. Arthritis following combined vaccine against diphtheria, polyomyelitis, and tetanus toxoid. Clin Exp Rheumatol 2000; 18: 255-256.
172. Vasudev M, Zacharisen MC. New-onset rheumatoid arthritis after anthrax vaccination. Ann Allergy Asthma Immunol 2006; 97: 110-112.
173. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009; 5: 648-652.
174. Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol 2000; 18: 181-184.